Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284141 | 0.86 | APLNR (0.55) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8520807 | 0.81 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL4150198 | 0.81 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL11525177 | 0.81 | MEN1 (0.56) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24514107 | 0.79 | APLNR (0.50) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL303868 | 0.78 | — | — | |
| SCHEMBL5073789 | 0.77 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL18329993 | 0.77 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8134537 | 0.77 | APLNR (0.44) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL1717954 | 0.77 | APLNR (0.48) | APLNRGAAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707842-A | Proteome targeting labeling capture probe and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-114716382-B | Continuous flow synthesis process of Ensifelvir intermediate of anti-new crown drug | 拓信达(启东)医药生物科技有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-114716382-A | Continuous flow synthesis process of anti-neocoronal drug Ensittrelvir intermediate | 拓信达(启东)医药生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2025236004-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| WO-2025131957-A1 | DIAZINONE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119707842-A | Proteome targeting labeling capture probe and preparation method and application thereof | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | disclosed |
| EP-4511128-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-5112968-A | Monobactam hydrazide derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-05-12 | — | — | US | disclosed |
| US-5077432-A | Monobactam hydrazides containing catechol sulfonic acid groups | E. R. SQUIBB & SONS, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| US-5037983-A | 6,7-dihydroxyquinoxalines as intermediates to beta-lactam antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0438752-A1 | Monobactam hydrazides containing catechol sulfonic acid groups | E.R. SQUIBB & SONS, INC. (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5030724-A | Monobactam hydrazides containing catechol sulfonic acid groups | E. R. SQUIBB & SONS, INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-4904775-A | Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics | E. R. SQUIBB & SONS, INC. (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0342423-A2 | Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics | E.R. SQUIBB & SONS, INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0196803-A2 | Benzene-fused heterocyclic compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| EP-0180352-A2 | Benzene-fused heterocyclic compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | APLNR 3903/4885GAA 1391/4885MEN1 2158/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | APLNR 3903/4885GAA 1391/4885MEN1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.